{"id":"eyedrop","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"4ab1adf6-8dff-7d51-e063-6294a90ae0b3","title":"ARTIFICIAL EYEDROP (SODIUM CHLORIDE) LIQUID [WATER BEAUTY INNOVATION CO. LTD.]"},"ecosystem":[],"_scrapedAt":"2026-03-28T01:53:11.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04774237","phase":"PHASE2","title":"Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","status":"COMPLETED","sponsor":"Visus Therapeutics","startDate":"2021-03-24","conditions":"Presbyopia","enrollment":18},{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66},{"nctId":"NCT07495670","phase":"NA","title":"Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients","status":"COMPLETED","sponsor":"Burapha University","startDate":"2024-11-04","conditions":"Diabetes (DM), Retinopathy, Diabetic, Pupil Dilation","enrollment":84},{"nctId":"NCT07495852","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":"Glaucoma","enrollment":510},{"nctId":"NCT07494799","phase":"","title":"Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2026-04-01","conditions":"Progressive Myopia, Pediatric Myopia, Orthokeratology-related Myopia Progression","enrollment":3890},{"nctId":"NCT07243275","phase":"PHASE4","title":"SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-02-18","conditions":"Dry Eye Disease (DED)","enrollment":260},{"nctId":"NCT06544694","phase":"PHASE3","title":"A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-08","conditions":"Dry Eye Disease","enrollment":80},{"nctId":"NCT06854393","phase":"PHASE2","title":"Lacripep for Corneal Wound Healing Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-05-23","conditions":"Corneal Epithelial Wound Healing","enrollment":88},{"nctId":"NCT07151612","phase":"PHASE4","title":"The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia","status":"COMPLETED","sponsor":"Shanxi Eye Hospital","startDate":"2025-09-04","conditions":"Presbyopia","enrollment":62},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":"Trachomatous Trichiasis (TT), Eye Diseases, Eyelid Diseases","enrollment":2410},{"nctId":"NCT07490535","phase":"PHASE4","title":"This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Pittsburgh Research Institute","startDate":"2026-03","conditions":"Ocular Surface Disease, Dry Eye Syndrome (DES)","enrollment":36},{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT05795699","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-03-30","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":107},{"nctId":"NCT05733572","phase":"PHASE2","title":"Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Benedetto Falsini","startDate":"2023-06-12","conditions":"Optic Pathway Glioma","enrollment":36},{"nctId":"NCT07354516","phase":"PHASE2, PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":36},{"nctId":"NCT06089317","phase":"NA","title":"Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2024-07-28","conditions":"Dry Eye Syndromes","enrollment":200},{"nctId":"NCT05577910","phase":"NA","title":"Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2022-10-08","conditions":"Meibomian Gland Dysfunction","enrollment":374},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT07480577","phase":"NA","title":"Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma","status":"NOT_YET_RECRUITING","sponsor":"Sakarya Yenikent State Hospital","startDate":"2026-04-01","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":84},{"nctId":"NCT06660290","phase":"PHASE3","title":"A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2025-01-15","conditions":"Dry Eye Disease","enrollment":55},{"nctId":"NCT06911424","phase":"PHASE3","title":"Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis","status":"RECRUITING","sponsor":"Baxis Pharmaceuticals, Inc.","startDate":"2025-03-21","conditions":"Bacterial Conjunctivitis","enrollment":400},{"nctId":"NCT06792903","phase":"EARLY_PHASE1","title":"YM-101 Eye Drops in the Treatment of Dry Eye Syndrome","status":"COMPLETED","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-04-23","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT07474883","phase":"EARLY_PHASE1","title":"Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Pham Ngoc Thach University of Medicine","startDate":"2026-03-09","conditions":"Post Inflammtory Erythema, Acne Vulgaris, Erythema","enrollment":60},{"nctId":"NCT07475585","phase":"NA","title":"Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve","status":"NOT_YET_RECRUITING","sponsor":"Fangbiao Tao","startDate":"2026-03-30","conditions":"Myopia, Ear Acupressure Pellets, Hyperopia Reserve","enrollment":380},{"nctId":"NCT05850936","phase":"NA","title":"Effect of IOP Lowering on Progressive HM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-01","conditions":"High Myopia, Intraocular Pressure","enrollment":152},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT05479123","phase":"PHASE4","title":"Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-06-23","conditions":"Infantile Hemangioma","enrollment":52},{"nctId":"NCT07284381","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-12-15","conditions":"Dry Eye Disease","enrollment":250},{"nctId":"NCT07469865","phase":"NA","title":"Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-11-30","conditions":"Dry Eye Disease","enrollment":46},{"nctId":"NCT04354545","phase":"","title":"Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":"Glaucoma, Ocular Surface Disease","enrollment":75},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT02846571","phase":"PHASE1, PHASE2","title":"Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye","status":"RECRUITING","sponsor":"Midhat H. Abdulreda","startDate":"2019-12-05","conditions":"Diabetes","enrollment":2},{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT07463950","phase":"PHASE4","title":"A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-20","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT05926258","phase":"PHASE3","title":"Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population","status":"COMPLETED","sponsor":"Sintetica SA","startDate":"2024-05-23","conditions":"Local Anesthetic","enrollment":74},{"nctId":"NCT05945615","phase":"PHASE3","title":"Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-01-11","conditions":"Blepharoptosis, Synkinesis, Hyperkinesis","enrollment":36},{"nctId":"NCT07457021","phase":"","title":"A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Ophthalmology Center Affiliated to Xiamen University","startDate":"2026-03-01","conditions":"Dry Eye Disease","enrollment":2000},{"nctId":"NCT07456826","phase":"PHASE4","title":"Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections","status":"NOT_YET_RECRUITING","sponsor":"Harrow Inc","startDate":"2026-04","conditions":"Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion","enrollment":236},{"nctId":"NCT07456488","phase":"PHASE2","title":"The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group","status":"RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07-13","conditions":"Focus on Axial Length","enrollment":60},{"nctId":"NCT07455916","phase":"NA","title":"Short-Term Effects of an AI-Based Wearable Adherence Monitor in Outpatient Psychiatry","status":"COMPLETED","sponsor":"Wonkwang University Hospital","startDate":"2022-12-31","conditions":"Mental Disease, Adherence to Care, Digital Health","enrollment":78},{"nctId":"NCT05273385","phase":"NA","title":"Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2022-10-10","conditions":"Glaucoma, Ocular Hypertension, Open Angle Glaucoma","enrollment":16},{"nctId":"NCT06388070","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2024-05-20","conditions":"Dry Eye Syndromes","enrollment":297},{"nctId":"NCT05692739","phase":"PHASE4","title":"Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye","status":"COMPLETED","sponsor":"Barbara Burgos Blasco","startDate":"2022-10-19","conditions":"Dry Eye, Insulin","enrollment":116},{"nctId":"NCT07449247","phase":"PHASE1, PHASE2","title":"PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2026-03-30","conditions":"Pre-myopia","enrollment":233},{"nctId":"NCT07449000","phase":"NA","title":"Losartan for Corneal Fibrosis","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2026-02-12","conditions":"Corneal Scarring Fibrosis","enrollment":46},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07095894","phase":"PHASE3","title":"A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control","status":"NOT_YET_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2026-03-01","conditions":"Myopia","enrollment":348},{"nctId":"NCT04704531","phase":"PHASE2","title":"Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2022-01-03","conditions":"Dry Eye","enrollment":141},{"nctId":"NCT07439809","phase":"NA","title":"The Effect of Periodic Intensive Education on Surgical Outcomes in Cataract Surgery Patients","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2025-07-30","conditions":"Cataract","enrollment":80},{"nctId":"NCT04923841","phase":"NA","title":"Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2021-09-09","conditions":"Myopia","enrollment":579},{"nctId":"NCT07075718","phase":"PHASE2, PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":"Glaucoma","enrollment":610},{"nctId":"NCT06806332","phase":"NA","title":"Glaucoma Drop Aids Part 2","status":"NOT_YET_RECRUITING","sponsor":"Boston Medical Center","startDate":"2026-04","conditions":"Glaucoma, Intraocular Pressure","enrollment":80},{"nctId":"NCT05728944","phase":"PHASE3","title":"Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-03-06","conditions":"Presbyopia, Near Vision, Refractive Error","enrollment":229},{"nctId":"NCT07434635","phase":"PHASE4","title":"APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Eye Disorders","enrollment":62},{"nctId":"NCT05656027","phase":"PHASE3","title":"Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-12-19","conditions":"Presbyopia, Refractive Error, Eye Diseases","enrollment":469},{"nctId":"NCT06190028","phase":"NA","title":"Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy","status":"TERMINATED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2023-06-14","conditions":"Dry Eye Syndrome, Glaucoma and Concomitant Dry Eye Syndrome, Ocular Hypertension and Concomitant Dry Eye Syndrome","enrollment":65},{"nctId":"NCT07291089","phase":"PHASE4","title":"Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-02-23","conditions":"Age Related Cataract, Pain Management During Cataract Surgery","enrollment":126},{"nctId":"NCT05978687","phase":"PHASE4","title":"The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2023-09-01","conditions":"Pterygium","enrollment":41},{"nctId":"NCT07354477","phase":"PHASE2","title":"Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-02-20","conditions":"Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)","enrollment":14},{"nctId":"NCT07425535","phase":"EARLY_PHASE1","title":"Optic Nerve Head Strain in Non-glaucoma Subjects","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT06030193","phase":"PHASE2","title":"Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2025-08-13","conditions":"Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye","enrollment":36},{"nctId":"NCT04702776","phase":"PHASE4","title":"Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-12-09","conditions":"Dry Eye","enrollment":182},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07422389","phase":"","title":"BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency","status":"AVAILABLE","sponsor":"BRIM Biotechnology Inc.","startDate":"","conditions":"Limbal Stem Cell Deficiency (LSCD)","enrollment":""},{"nctId":"NCT07422259","phase":"NA","title":"Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed","status":"COMPLETED","sponsor":"Medivis SRL","startDate":"2025-06-09","conditions":"Keratoconjunctivitis Sicca","enrollment":40},{"nctId":"NCT07419776","phase":"","title":"The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-06-24","conditions":"Poly Cystic Ovary Syndrome","enrollment":90},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT06224673","phase":"PHASE2","title":"ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Laura Huppert, MD, BA","startDate":"2026-03-01","conditions":"HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer","enrollment":36},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT06636708","phase":"PHASE4","title":"Efficacy of Nanodropper-mediated Topical Anesthetic","status":"COMPLETED","sponsor":"Columbia University","startDate":"2024-12-12","conditions":"Corneal Diseases, Effectiveness of Microdrops","enrollment":56},{"nctId":"NCT07407101","phase":"NA","title":"Impact of Filtration on Autologous Serum Eye Drops","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2026-04-30","conditions":"Dry Eye Syndrome (DES)","enrollment":10},{"nctId":"NCT06859476","phase":"PHASE4","title":"Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-05-23","conditions":"Ophthalmological Agent Toxicity","enrollment":168},{"nctId":"NCT07406399","phase":"PHASE4","title":"Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2023-06-30","conditions":"High Myopia, Low Concentration Atropine, Soft Contact Lens","enrollment":120},{"nctId":"NCT07028827","phase":"PHASE3","title":"Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)","status":"RECRUITING","sponsor":"Ocus Innovation Ireland Limited","startDate":"2025-09-01","conditions":"Myopia","enrollment":234},{"nctId":"NCT07400952","phase":"PHASE2","title":"Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":100},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":"Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain","enrollment":30},{"nctId":"NCT06544707","phase":"PHASE3","title":"A Study Designed to Evaluate Tear Production","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-15","conditions":"Dry Eye Disease","enrollment":81},{"nctId":"NCT07397949","phase":"PHASE4","title":"Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-03","conditions":"Dry Eye Disease (DED), Cataract","enrollment":60},{"nctId":"NCT07384767","phase":"PHASE2","title":"Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Mohs Micrographic Surgery, Excision Margin","enrollment":220},{"nctId":"NCT07396831","phase":"","title":"Necessity of Post-operative Eye Drops","status":"TERMINATED","sponsor":"Loma Linda University","startDate":"2024-04-09","conditions":"Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes","enrollment":48},{"nctId":"NCT07397936","phase":"PHASE4","title":"Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-08-01","conditions":"Dry Eye Disease (DED), Cataract","enrollment":55},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":"Atopic Keratoconjunctivitis","enrollment":138},{"nctId":"NCT06659549","phase":"PHASE2","title":"A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD","status":"RECRUITING","sponsor":"Galimedix Therapeutics Inc","startDate":"2025-01-10","conditions":"Geographic Atrophy of the Macula","enrollment":110},{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT07370584","phase":"PHASE1","title":"A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults","status":"RECRUITING","sponsor":"iVeena Delivery Systems, Inc.","startDate":"2026-02-04","conditions":"Safety Study","enrollment":36},{"nctId":"NCT05865457","phase":"NA","title":"Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"TRB Chemedica International SA","startDate":"2025-09-25","conditions":"Dry Eye Disease","enrollment":80},{"nctId":"NCT05865379","phase":"NA","title":"Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"TRB Chemedica International SA","startDate":"2026-03","conditions":"Dry Eye Disease","enrollment":80},{"nctId":"NCT07390578","phase":"PHASE4","title":"Upneeq vs. Lumify Ptosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-01","conditions":"Acquired Ptosis","enrollment":50},{"nctId":"NCT05470881","phase":"PHASE1","title":"Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2022-08-20","conditions":"Myopia","enrollment":29},{"nctId":"NCT07388069","phase":"PHASE1, PHASE2","title":"Study of TN-001 Topical Eyedrops for Keratoconus","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT07382453","phase":"PHASE2","title":"Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-15","conditions":"Diabetic Keratopathy","enrollment":30},{"nctId":"NCT06852768","phase":"PHASE1, PHASE2","title":"Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)","status":"RECRUITING","sponsor":"Regenerative Ocular Immunobiologics LLC","startDate":"2025-01-10","conditions":"oGHVD","enrollment":1},{"nctId":"NCT07124910","phase":"PHASE3","title":"Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases","status":"RECRUITING","sponsor":"Woolfson Eye Institute","startDate":"2025-08-01","conditions":"Keratoconus, Ectasia of Cornea, Pellucid Marginal Corneal Degeneration","enrollment":485},{"nctId":"NCT07135167","phase":"PHASE3","title":"Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome","status":"RECRUITING","sponsor":"Woolfson Eye Institute","startDate":"2025-08-01","conditions":"Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration","enrollment":225},{"nctId":"NCT01471184","phase":"NA","title":"The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2009-09","conditions":"Allergic Rhinitis, Allergic Conjunctivitis","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":892,"therapeuticAreas":["Ophthalmology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Eyedrop","genericName":"Eyedrop","companyName":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","companyId":"lundquist-institute-for-biomedical-innovation-at-harbor-ucla-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}